HCW Biologics Inc. (HCWB)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2020
Novel Immunotherapies	2.84M	Log In	Log In
Novel Immunotherapies Growth	-57.72%	Log In	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2020
United States	2.84M	Log In	Log In
United States Growth	-57.72%	Log In	Log In